Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
Portfolio Pulse from Vandana Singh
Relmada Therapeutics Inc (NASDAQ:RLMD) announced positive results from the Phase 3 trial of REL-1017 in patients with Major Depressive Disorder (MDD). The trial showed rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment. The drug was well-tolerated with low rates of adverse events. The news led to a 7.53% increase in RLMD shares.
September 20, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive results from the Phase 3 trial of REL-1017 in patients with Major Depressive Disorder (MDD) led to a 7.53% increase in RLMD shares.
The positive results from the Phase 3 trial of REL-1017 indicate that the drug is effective and well-tolerated. This is likely to increase investor confidence in the company and its product, leading to an increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100